Grant Number:	5U01CA224255-06 Interpret this number
Primary Investigator:	Lin, Daniel
Organization:	Fred Hutchinson Cancer Center
Project Title:	Prostate Cancer Active Surveillance Study (PASS) Cohort: Infrastructure Support for Cancer Research
Fiscal Year:	2023

PROJECT SUMMARY/ABSTRACT We propose to support the established Prostate cancer Active Surveillance Study (PASS) cohort, which is a large multi-institutional cohort of men with clinically localized prostate cancer who have elected active surveillance to manage their cancer. With broad eligibility criteria designed to represent the population of men who utilize active surveillance, the cohort has over 2,100 participants with extensive clinical and epidemiological data (demographic, lifestyle, quality of life, long-term outcomes) and longitudinal biospecimens (germline DNA, serum, plasma, urine, and prostate tissue) collected according to a standardized protocol. The cohort was established in 2008 in response to the growing evidence of prostate cancer overtreatment and the need for a prospective study to discover and validate biomarkers of prostate cancer progression, and to identify determinants of cancer progression and patient outcomes. Over the past decade, the cohort has amassed a wealth of data and biospecimens so that it serves as the foundation for addressing critical questions relevant to the optimal personalized management of early stage prostate cancer. The successful funding of this application will support a robust infrastructure for PASS that in turn will ensure the availability of PASS data and specimens to facilitate research addressing determinants of cancer progression, recurrence, and outcomes. A substantial proportion of these research endeavors are encompassed in currently funded federal grants, and the successful completion of the current and future projects relies on the continued success of the PASS enterprise. The impact of this cohort lies in its potential to investigate research questions of paramount importance: to identify better prognostic markers of prostate cancer aggressiveness; to understand the clinical management, progression and outcomes of early stage prostate cancer; to tailor the approach of active surveillance based on individual characteristics and preferences; to characterize associations between clinicopathologic factors, patient lifestyle, and disease biology; to develop new tools to communicate medical information to patients; and to understand decision- making among patients on active surveillance, in particular with regards to quality of life, anxiety, and regret . The successful completion of these transformative research endeavors will address unmet needs in the most commonly diagnosed male cancer and substantially reduce the current public health burden of early stage prostate cancer.




Magnetic Resonance Imaging at Second Surveillance Biopsy After Diagnosis in Patients With Grade Group 1 Prostate Cancer in the Canary Prostate Active Surveillance Study.
Authors: Chappidi M.R. , Newcomb L.F. , Zheng Y. , Liu M. , Schenk J.M. , Zhu K. , de la Calle C.M. , Brooks J.D. , Carroll P.R. , Dash A. , et al. .
Source: The Journal Of Urology, 2025 Sep; 214(3), p. 251-258.
EPub date: 2025-04-30 00:00:00.0.
PMID: 40305682
Related Citations

Proposal for an optimised definition of adverse pathology (unfavourable histology) that predicts metastatic risk in prostatic adenocarcinoma independent of grade group and pathological stage.
Authors: Nguyen J.K. , Harik L.R. , Klein E.A. , Li J. , Corrigan D. , Liu S. , Chan E. , Hawley S. , Auman H. , Newcomb L.F. , et al. .
Source: Histopathology, 2024 Oct; 85(4), p. 598-613.
EPub date: 2024-06-03 00:00:00.0.
PMID: 38828674
Related Citations

Long-Term Outcomes in Patients Using Protocol-Directed Active Surveillance for Prostate Cancer.
Authors: Newcomb L.F. , Schenk J.M. , Zheng Y. , Liu M. , Zhu K. , Brooks J.D. , Carroll P.R. , Dash A. , de la Calle C.M. , Ellis W.J. , et al. .
Source: Jama, 2024-06-25 00:00:00.0; 331(24), p. 2084-2093.
PMID: 38814624
Related Citations

Dietary Patterns and Risk of Gleason Grade Progression among Men on Active Surveillance for Prostate Cancer: Results from the Canary Prostate Active Surveillance Study.
Authors: Schenk J.M. , Liu M. , Neuhouser M.L. , Newcomb L.F. , Zheng Y. , Zhu K. , Brooks J.D. , Carroll P.R. , Dash A. , Ellis W.J. , et al. .
Source: Nutrition And Cancer, 2023; 75(2), p. 618-626.
EPub date: 2022-11-07 00:00:00.0.
PMID: 36343223
Related Citations

Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance.
Authors: Brady L. , Newcomb L.F. , Zhu K. , Zheng Y. , Boyer H. , Sarkar N. , McKenney J.K. , Brooks J.D. , Carroll P.R. , Dash A. , et al. .
Source: Cancer Medicine, 2022 Nov; 11(22), p. 4332-4340.
EPub date: 2022-04-25 00:00:00.0.
PMID: 35467778
Related Citations

Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance.
Authors: Filson C.P. , Zhu K. , Huang Y. , Zheng Y. , Newcomb L.F. , Williams S. , Brooks J.D. , Carroll P.R. , Dash A. , Ellis W.J. , et al. .
Source: The Journal Of Urology, 2022 Nov; 208(5), p. 1037-1045.
EPub date: 2022-07-05 00:00:00.0.
PMID: 35830553
Related Citations

Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results from the Canary PASS Cohort.
Authors: Waisman Malaret A.J. , Chang P. , Zhu K. , Zheng Y. , Newcomb L.F. , Liu M. , McKenney J.K. , Brooks J.D. , Carroll P. , Dash A. , et al. .
Source: The Journal Of Urology, 2022 Apr; 207(4), p. 805-813.
EPub date: 2021-12-02 00:00:00.0.
PMID: 34854745
Related Citations

Treatment in the absence of disease reclassification among men on active surveillance for prostate cancer.
Authors: Kirk P.S. , Zhu K. , Zheng Y. , Newcomb L.F. , Schenk J.M. , Brooks J.D. , Carroll P.R. , Dash A. , Ellis W.J. , Filson C.P. , et al. .
Source: Cancer, 2022-01-15 00:00:00.0; 128(2), p. 269-274.
EPub date: 2021-09-13 00:00:00.0.
PMID: 34516660
Related Citations

Genetic Factors Associated with Prostate Cancer Conversion from Active Surveillance to Treatment.
Authors: Jiang Y. , Meyers T.J. , Emeka A.A. , Cooley L.F. , Cooper P.R. , Lancki N. , Helenowski I. , Kachuri L. , Lin D.W. , Stanford J.L. , et al. .
Source: Hgg Advances, 2022-01-13 00:00:00.0; 3(1), .
EPub date: 2021-11-19 00:00:00.0.
PMID: 34993496
Related Citations

Factors Associated with Time to Conversion from Active Surveillance to Treatment for Prostate Cancer in a Multi-Institutional Cohort.
Authors: Cooley L.F. , Emeka A.A. , Meyers T.J. , Cooper P.R. , Lin D.W. , Finelli A. , Eastham J.A. , Logothetis C.J. , Marks L.S. , Vesprini D. , et al. .
Source: The Journal Of Urology, 2021 Nov; 206(5), p. 1147-1156.
EPub date: 2021-09-10 00:00:00.0.
PMID: 34503355
Related Citations

Magnetic Resonance Imaging for the Detection of High Grade Cancer in the Canary Prostate Active Surveillance Study.
Authors: Liss M.A. , Newcomb L.F. , Zheng Y. , Garcia M.P. , Filson C.P. , Boyer H. , Brooks J.D. , Carroll P.R. , Cooperberg M.R. , Ellis W.J. , et al. .
Source: The Journal Of Urology, 2020 Oct; 204(4), p. 701-706.
EPub date: 2020-04-28 00:00:00.0.
PMID: 32343189
Related Citations

Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability.
Authors: Cooperberg M.R. , Zheng Y. , Faino A.V. , Newcomb L.F. , Zhu K. , Cowan J.E. , Brooks J.D. , Dash A. , Gleave M.E. , Martin F. , et al. .
Source: Jama Oncology, 2020-10-01 00:00:00.0; 6(10), p. e203187.
EPub date: 2020-10-08 00:00:00.0.
PMID: 32852532
Related Citations

17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort.
Authors: Lin D.W. , Zheng Y. , McKenney J.K. , Brown M.D. , Lu R. , Crager M. , Boyer H. , Tretiakova M. , Brooks J.D. , Dash A. , et al. .
Source: Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology, 2020-05-10 00:00:00.0; 38(14), p. 1549-1557.
EPub date: 2020-03-04 00:00:00.0.
PMID: 32130059
Related Citations

African American Race is Not Associated with Risk of Reclassification during Active Surveillance: Results from the Canary Prostate Cancer Active Surveillance Study.
Authors: Schenk J.M. , Newcomb L.F. , Zheng Y. , Faino A.V. , Zhu K. , Nyame Y.A. , Brooks J.D. , Carroll P.R. , Cooperberg M.R. , Dash A. , et al. .
Source: The Journal Of Urology, 2020 Apr; 203(4), p. 727-733.
EPub date: 2019-10-25 00:00:00.0.
PMID: 31651227
Related Citations